A novel recombinant javanicin with dual antifungal and anti-proliferative activities

• Main Authors: Santhasiri Orrapin, Amornrat Intorasoot, Sittiruk Roytrakul, Nathupakorn Dechsupa, Jiraporn Kantapan, Yanika Onphat, Chutima Srimek, Chayada Sitthidet Tharinjaroen, Usanee Anukool, Bordin Butr-Indr, Ponrut Phunpae, Sorasak Intorasoot
• Format: Journal
• Published: 2020
• Subjects: Multidisciplinary
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85075967653&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/68117
• Institution: Chiang Mai University

© 2019, The Author(s). Resistance to common drugs by microorganisms and cancers has become a major issue in modern healthcare, increasing the number of deaths worldwide. Novel therapeutic agents with a higher efficiency and less side effects for the treatment of certain diseases are urgently needed. Plant defensins have an integral role in a hosts’ immune system and are attractive candidates for combatting drug-resistant microorganisms. Interestingly, some of these defensins also showed great potential due to their cytotoxic activity toward cancer cells. In this study, a defensin encoding gene was isolated from five legume seeds using 3′ rapid amplification of cDNA ends (3′ RACE) with degenerate primers and cDNA cloning strategies. Bioinformatic tools were used for in silico identification and the characterization of new sequences. To study the functional characteristics of these unique defensins, the gene encoded for Sesbania javanica defensin, designated as javanicin, was cloned into pTXB-1 plasmid and expressed in the Escherichia coli Origami 2 (DE3) strain. Under optimized conditions, a 34-kDa javanicin-intein fusion protein was expressed and approximately 2.5–3.5 mg/L of soluble recombinant javanicin was successfully extracted with over 90% purity. Recombinant javanicin displayed antifungal properties against human pathogenic fungi, including resistant strains, as well as cytotoxic activities toward the human breast cancer cell lines, MCF-7 & MDA-MB-231. Recombinant javanicin holds great promise as a novel therapeutic agent for further medical applications.